BGB-108 / BeOne Medicines - LARVOL DELTA

DUBHE-L-303: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=606 | Active, not recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

DUBHE-L-303: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=650 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2025 ➔ Dec 2029 | Trial primary completion date: Jun 2025 ➔ Jun 2029

Enrollment open • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=650 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Combination therapy • Metastases • New P3 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1